So­tio ter­mi­nates three tri­als study­ing its IL-15 su­per­ag­o­nist due to ‘in­suf­fi­cient ef­fi­ca­cy’

Czech biotech So­tio is im­me­di­ate­ly scrap­ping three clin­i­cal tri­als of its in­ter­leukin-15 su­per­ag­o­nist called nan­rilke­fusp al­fa af­ter in­ter­im da­ta showed “in­suf­fi­cient ef­fi­ca­cy.”

“While we are dis­ap­point­ed with this out­come, we will con­tin­ue to gath­er and an­a­lyze the full body of da­ta from these stud­ies to in­form our fu­ture de­vel­op­ment plans for nan­rilke­fusp al­fa,” So­tio chief med­ical of­fi­cer Richard Sachse said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER